RxDoctor Payments Data

Daniel Flaherty, DO

Family Medicine · Rochester, NYNPI 1659339976

Payments from drug & device makers

$7,215in general payments, 2019–2025

Across 82 payments — averaging $87.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$6K
  • Novo Nordisk$541
  • AbbVie$205
  • Amgen$25
  • Boehringer Ingelheim$22
  • Lilly USA, LLC$19
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$860100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,215 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$35,450
Medicare patients
100
Services billed
662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban146$132,716
Trelegy ElliptaFluticasone/Umeclidin/Vilanter109$100,849
OzempicSemaglutide81$98,221
JardianceEmpagliflozin69$82,448
XareltoRivaroxaban64$57,028
SynjardyEmpagliflozin/Metformin Hcl33$49,635
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$27,009
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr39$22,936
Synjardy XrEmpagliflozin/Metformin Hcl18$22,804
Tresiba Flextouch U-100Insulin Degludec17$20,185
FarxigaDapagliflozin Propanediol14$19,257
Lantus SolostarInsulin Glargine,hum.Rec.Anlog115$16,630
PaxlovidNirmatrelvir/Ritonavir25$16,225
JanumetSitagliptin Phos/Metformin Hcl14$16,110
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$15,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$22$154,886120 claims
Novo NordiskOzempic$541$98,22181 claims
AstraZenecaFarxiga, Breztri Aerosphere$15$30,93025 claims
Lilly USA, LLCTrulicity$19$13,53014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →